ALBO Albireo Pharma Inc.

23.37
+0.22  (+1%)
Previous Close 23.15
Open 22.51
Price To Book 2.92
Market Cap 296,485,281
Shares 12,686,576
Volume 31,714
Short Ratio
Av. Daily Volume 83,760
Stock charts supplied by TradingView

NewsSee all news

  1. Albireo Joins with Alagille Syndrome Community in Celebrating First International Awareness Day

    BOSTON, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, commemorates the first International Alagille

  2. Albireo to Present at the Jefferies 2019 London Healthcare Conference

    BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President

  3. Albireo Reports Third Quarter 2019 Financial Results and Provides Business Update

    — Phase 3 PFIC trial randomization more than three-quarters complete. —— Topline results expected mid-2020. —— Pivotal trial in biliary atresia expected to be initiated in 2020.  —— Management to host conference call and

  4. Albireo to Report Third Quarter 2019 Financial Results on November 6, 2019

    BOSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a

  5. Albireo Recognizes PFIC Awareness Day and Highlights Urgent Needs of Progressive Familial Intrahepatic Cholestasis Families

    BOSTON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today its support for PFIC

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 top-line data due mid-2020.
Odevixibat (A4250) - PEDFIC- 1
Progressive familial intrahepatic cholestasis (PFIC)
Phase 2 data due mid-2020.
Elobixibat
Nonalcoholic steatohepatitis (NASH)
Phase 3 trial planned for 2020.
Odevixibat (A4250)
Biliary atresia

Latest News

  1. Albireo Joins with Alagille Syndrome Community in Celebrating First International Awareness Day

    BOSTON, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, commemorates the first International Alagille

  2. Albireo to Present at the Jefferies 2019 London Healthcare Conference

    BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President

  3. Albireo Reports Third Quarter 2019 Financial Results and Provides Business Update

    — Phase 3 PFIC trial randomization more than three-quarters complete. —— Topline results expected mid-2020. —— Pivotal trial in biliary atresia expected to be initiated in 2020.  —— Management to host conference call and

  4. Albireo to Report Third Quarter 2019 Financial Results on November 6, 2019

    BOSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a

  5. Albireo Recognizes PFIC Awareness Day and Highlights Urgent Needs of Progressive Familial Intrahepatic Cholestasis Families

    BOSTON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today its support for PFIC

  6. Albireo Announces Presentations at NASPGHAN 2019 Annual Meeting

    BOSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced upcoming presentations at

  7. Albireo to Participate in Upcoming Investor Conferences

    BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Simon Harford, Chief